Medivir: Encouraging results with remetinostat

Research Note

2019-05-14

07:48

The recently announced interim results from the phase II trial with remetinostat in basal cell carcinoma (BCC) patients are promising and indicates a differentiation compared to existing treatment options. Data suggests remetinostat may reduce the necessity of surgery in some BCC patients. The last patient is expected to complete the trial in December 2019.

KP

Klas Palin

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.